Quarterly ResultMay 6, 2026, 04:22 PM
GoodRx Q1 Net Income Plunges to $1.17M; EPS $0.00
AI Summary
GoodRx Holdings, Inc. reported a substantial decline in its first-quarter 2026 financial results, with net income plummeting to $1.17 million from $11.05 million in the prior year. Revenue also decreased by 4.4% to $194.01 million. The company's diluted earnings per share fell to $0.00, down from $0.03. Additionally, GoodRx is navigating ongoing legal proceedings related to a consumer privacy class action, with a proposed $25.0 million settlement still awaiting court approval.
Key Highlights
- Q1 2026 Revenue decreased 4.4% to $194.01 million.
- Q1 2026 Net Income fell 89.4% to $1.17 million.
- Diluted EPS for Q1 2026 was $0.00, down from $0.03.
- Operating income for Q1 2026 decreased 40% to $14.01 million.
- Net cash from operating activities increased to $11.84 million.
- Accrued legal settlement of $30.50 million remains.
- Share repurchases totaled $12.57 million in Q1 2026.
Price Impact
More from GDRX